V. López-Valverde

Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study

P. Fasching, W. Symmans, V. Valero, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

LBA14 Neoadjuvant giredestrant (GDC-9545) + palbociclib (palbo) vs anastrozole (A) + palbo in post-menopausal women with oestrogen receptor-positive, HER2-negative, untreated early breast cancer (ER+/HER2– eBC): Interim analysis of the randomised, open-label, phase II coopERA BC study

P. Fasching, A. Bardia, S. Hurvitz, 2021, Annals of Oncology.

Tumor biomarkers and efficacy in patients treated with trastuzumab emtansine + pertuzumab versus standard of care in HER2-positive early breast cancer: an open-label, phase III study (KRISTINE)

D. Slamon, M. Press, A. Prat, 2023, Breast Cancer Research.

Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the MEK Inhibitor RO4987655 (CH4987655) in Patients with Advanced Solid Tumors

J. Schellens, R. Rueger, M. Scheulen, 2012, Clinical Cancer Research.

Cancer Therapy: Clinical Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the MEK Inhibitor RO4987655 (CH4987655) in Patients with Advanced Solid Tumors

J. Schellens, R. Rueger, M. Scheulen, 2012 .

Neoadjuvant giredestrant (GDC-9545) plus palbociclib (P) versus anastrozole (A) plus P in postmenopausal women with estrogen receptor–positive, HER2-negative, untreated early breast cancer (ER+/HER2– eBC): Final analysis of the randomized, open-label, international phase 2 coopERA BC study.

P. Fasching, A. Bardia, Yeon-Hee Park, 2022, Journal of Clinical Oncology.

Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study.

A. Bardia, Yeon-Hee Park, D. Yardley, 2023, The Lancet. Oncology.

Cancer Therapy: Clinical Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the MEK Inhibitor RO4987655 (CH4987655) in Patients with Advanced Solid Tumors

J. Schellens, R. Rueger, M. Scheulen, 2012 .